Clinical Study of CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

  Entering the 21st century ,several tumor immunotherapy success in clinical trial make the immunotherapy very hot in research field. Especially after 2010, CAR-T cell immunotherapy have an amazing effect on B cell Malignant Tumors.   The CR is more than 85% in Relapsed or Refractory ALL patients,and the ORR up to 60% in B-cell Lymphoma patients.

What is CAR-T cell immunotherapy? T cells are collected from a patient,they are genetically engineered to produce chimeric antigen receptors (CARs) on their surface.After this reengineering, the T cells are known as “chimeric antigen receptor (CAR) T cells.” CARs are proteins that allow the T cells to recognize an antigen on targeted tumor cells.The CAR T cells are then infused into the patient and they are the “attacker” cells that will recognize, and kill, cancerous cells that have the targeted antigen on their surface.

  

Hebei Senlang Biotechnology Co., Ltd together Second Hospital of Hebei Medical University develop the CAR-T cell immunotherapy clinical study ,use the CD19 as target for CD19+ Patients With Relapsed or Refractory Blood Malignant Tumors ( main including ALL and B-cell Lymphoma)



  This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric   antigen receptor T cell immunotherapy (CAR-T) in the treatment of hematopoietic and   lymphoid malignancies.A total of 30 patients are planned to be enrolled over a period of 2 years.


快乐飞艇综合走势图 快乐飞艇做任务靠谱吗 熊猫乐园快乐飞艇 华创投资快乐飞艇靠谱吗 快乐飞艇app首页 快乐飞艇计划 快乐飞艇app下载 快乐飞艇官网 快乐飞艇技巧 快乐飞艇开奖